Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls

Author:

Adeleke Sola123ORCID,Haslam Aidan4,Choy Adrian5,Diaz-Cano Salvador67,Galante Joao R8ORCID,Mikropoulos Christos9,Boussios Stergios91011ORCID

Affiliation:

1. High Dimensional Neurology Group, UCL Queen’s Square Institute of Neurology, London, WC1N 3BG, UK

2. Department of Oncology, Guy’s & St Thomas’ Hospital, London, UK

3. School of Cancer & Pharmaceutical Sciences, King’s College London, Strand, London, WC2R 2LS, UK

4. South Bristol Academy, Dolphin House, Bristol Royal Infirmary, Marlborough Street, BS2 8HW, UK

5. Department of Oncology, Oxford University Hospitals, NHS Foundation Trust, Headington, Oxford, OX3 7DQ, UK

6. Department of Cellular Pathology, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Edgbaston, Birmingham, B15 2TH, UK

7. Medway NHS Foundation Trust, Windmill Road, Gillingham, Kent, ME7 5NY, UK

8. Maidstone Hospital, Hermitage Lane, Maidstone, Kent, ME16 9QQ, UK

9. Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham, Kent, ME7 5NY, UK

10. King’s College London, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, London, SE1 9RT, UK

11. AELIA Organization, 9th Km Thessaloniki, Thermi, Thessaloniki, 57001, Greece

Abstract

We present the case of a patient with Lynch syndrome and metastatic colorectal carcinoma (mCRC). The initial immunohistochemistry (IHC) test for deficient mismatch repair gave a false negative result. However, the same mutation has accurately been detected with IHC in other cancers with microsatellite instability (MSI). This supports the determining role of somatic missense mutations in MMR IHC. MSI-PCR testing confirmed MSI and the patient benefited from nivolumab with a complete metabolic response. We explain the rationale for immunotherapy in mCRC, current testing strategies and discuss future developments in MSI testing. We advocate for upfront testing using both IHC and MSI-PCR to direct therapy in mCRC, and a greater understanding of IHC and MSI-PCR testing pitfalls.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3